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ABSTRACT 
Cancer is a potentially fatal disease, where cells abnormally divide which hurts the tissues. The incidences of cancer are increasing worldwide and 
become one of the leading causes of death. A numbers of anticancer agents are available in the market or under clinical trials used for its treatment, 
but unfortunately, none of them is able to treat cancer. Thus, the exploration of novel mechanistic pathways of existing molecules may help to 
develop more effective anticancer agents. Efavirenz, a well-known non-nucleoside reverse transcriptase inhibitor, used in the highly active 
antiretroviral therapy (HAART) for the treatment of human immunodeficiency virus (HIV) infected patients with tolerable side effects. Newly 
emerging data revealed that efavirenz has the potential to induce toxic effects against a wide range of cancer cells by altering various cancer 
pathways. Thus, this existing antiretroviral drug with already known safety profiles could be rapidly utilized for the treatment of various cancers.  
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Cancer is a leading cause of death which is characterized by 
uncontrolled growth and spread of abnormal cells in the body whose 
exact etiology is unknown, but 90-95% cases are due to the 
environmental factors [1, 2]. For the treatment of cancer, various 
options are available such as surgery, chemotherapy, radiation 
therapy, hormonal therapy, targeted therapy and palliative care 
depends on the type, location, and grade of cancer as well as the 
person's health, but instead of that incidence of cancer keeps 
increasing on a global scale. Mostly all of the anticancer drugs show 
various side effects such as unwanted hair loss, sometimes potentially 
life-threatening conditions such as anemia and various infections [3, 
4]. In the present situation, there is no safe and effective cancer 
therapy available due to lack of knowledge of the exact mechanism of 
anticancer agents and their side effects. Thus, there is an urgent need 
of novel molecules with novel mechanistic pathways which may help 
to develop more effective anticancer agents.  
The endogenous reverse transcriptase plays an important role in the 
mechanism of cancer which is only activated in cancer cells and 
essential for their malignancy. Targeting of the endogenous reverse 
transcriptase specifically in tumors is the most promising approach 
in the field of oncology [5, 6]. Efavirenz (EFV) is a well-known 
antiretroviral drug (approved by FDA in 1997) widely used to treat 
human immunodeficiency virus (HIV) patients in combination with 
protease inhibitors, inhibits the endogenous reverse transcriptase in 
various cancer cells, thus, here I propose that efavirenz could be a 
potential anticancer agent.  
The survival of HIV-1-infected patients is prolonged, and causes of 
death have changed due to the introduction of highly active 
antiretroviral therapy (HAART). In the literature, some reports have 
shown that the incidence of precancerous lesions in HIV-1-infected 
patients on HAART is less as compared with patients without 
HAART [7-9]. From these reports, it can be concluded that the 
decrease incidence of cancer is may be due to an anti-neoplastic 
effect of the drugs used in HAART. 
Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor 
(NNRTI) which is used as part of HAART for the treatment of a HIV 
[10]. Emerging reports indicate that efavirenz induces the anticancer 
effect in various cells [11, 12]. This effect might be based on several 
different mechanisms such as the inhibition of endogenous reverse 
transcriptase, inhibition of the activity of tumor-promoting retro-
elements and activation of oxidative stress mitochondrial-dependent 
apoptotic signaling pathways as shown in fig. 1. 
The NNRTI, EFV is toxic against a wide range of cancer cells and only 
have a minor toxicity against normal tissue cells (fig. 1) [13]. 
Sinibaldi-Vallebona et al. [14] reported the anticancer effect of 
efavirenz in mice. As efavirenz is very well-tolerated in HIV 
treatment, so it could also be a promising for cancer treatment. 
In a recent report, Patnala et al. (2014) demonstrated that efavirenz 
at low concentration (15 & 45 μM) inhibiting the activity of tumor-
promoting retro elements, leading to a reduction in the rate of 
breast cancer proliferation. Further, this study has shown that 
efavirenz modulates the various genes expressions, but the 
underlying mechanism is still not cleared. These results indicate that 
efavirenz at lower concentration is a potent anticancer agent in the 
breast cancer [12]. 
 
 
Fig. 1: Effect of Efavirenz at a lower concentration in normal 
and cancer cells. In normal cells, efavirenz produces tolerable 
damage but in cancer cells, efavirenz inhibits the endogenous 
reverse transcriptase, tumor promoting retroelements along 
with activation of apoptotic pathways which provide a new 
hope as anticancer agent. fig. has been drawn by Bio Chemdraw. 
 
Among all non-nucleoside reverse transcriptase inhibitors, efavirenz 
has the highest antiproliferative effect with EC50s of 31.5μmol/l and 
49.0μmol/l, against pancreatic BxPC-3 and Panc-1 cancer cell lines 
respectively. Further, this study compares the in vitro toxicity to 
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blood levels of HIV-positive patients and suggested that the in vitro 
toxic concentrations of efavirenz against cancer cells can be 
achieved in vivo in a low percentage of patients without increasing 
the standard dose of 600 mg EFV daily [11]. Thus, low dose 
efavirenz may have a beneficial effect by modulating various 
anticancer signaling pathways in the cancer cells which is 
summarized in the fig. 1.  
The notion of an antiviral drug as a potential anticancer agent could 
be strange but we know that the therapeutic effect of many medical 
agents is far from their original use. For example, prontosil which is 
a coloring agent found to have antibacterial activities and became 
the first synthetic drug used in the treatment of general bacterial 
infections in humans. Recently, I also proposed the use of pyrethroid 
insecticide, deltamethrin as an anticancer agent [15]. I believe that 
efavirenz can also improve cancer management by inhibiting the 
various cancer pathways. Because it is an existing drug with known 
pharmacokinetics and safety profiles and is currently in use, so, it 
can be rapidly evaluated in clinical trials to evaluate its effect on 
various cancers.  
The mechanisms underlying the anticancer effect of efavirenz on 
cancer cell are still unclear. Thus, in future studies, further 
exploration of the anticancer mechanisms of efavirenz should be 
evaluated which will be helpful for researchers to design efavirenz 
as a novel anticancer agent. 
ACKNOWLEDGEMENT 
Author acknowledges Department of Science and Technology (DST) 
for financial support in the form of DST-INSPIRE fellowship [IF 
120789]. 
CONFLICT OF INTERESTS 
Author declares that he has no conflict of interest. 
REFERENCES 
1. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M. 
Causes of cancer in the world: comparative risk assessment of 
nine behavioral and environmental risk factors. Lancet 
2005;366:1784-93.  
2. Boffetta P, Nyberg F. Contribution of environmental factors to 
cancer risk. Br Med Bull 2003;68:71-94.  
3. Remesh A. Toxicities of anticancer drugs and its management. 
Int J Basic Clin Pharmacol 2012;1:2-12. 
4. Donaldson KL, Goolsby GL, Wahl AF. Cytotoxicity of the antican
cer agents cisplatin and taxol during cell proliferation and the c
ell cycle. Int J Cancer 1994;57:847-55.  
5. Sciamanna I, Landriscina M, Pittoggi C. Inhibition of 
endogenous reverse transcriptase antagonizes human tumor 
growth. Oncogene 2005;24:3923-31. 
6. Landriscina M, Spadafora C, Cignarelli M, Barone C. Anti-tumor 
activity of non-nucleosidic reverse transcriptase inhibitors. 
Curr Pharm Des 2007;13:737-47. 
7. Bonnet F, Burty C, Lewden C. Changes in cancer mortality 
among HIV-infected patients: the mortalite 2005 survey. Clin 
Infect Dis 2009;48:633–9.  
8. Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B. 
Antitumour effects of antiretroviral therapy. Nat Rev Cancer 
2004;4:861-75. 
9. Coutinho RA. Highly active antiretroviral therapy and incidence 
of cancer in human immunodeficiency virus-infected adults. J 
Natl Cancer Inst 2000;92:1823-30.  
10. Dinaker M. Combination antiretroviral therapy (CART)- rationa
le  and recommendation. Medicine 2011;507-10. 
11. Hecht M, Erber S, Harrer T. Efavirenz has the highest 
antiproliferative effect of non-nucleoside reverse transcriptase 
inhibitors against pancreatic cancer cells. PloS One 
2015;10:e0130277. Doi:10.1371/journal.pone.0130277. 
[Article in Press] 
12. Patnala R, Lee SH, Dahlstrom JE. Inhibition of LINE-1 
retrotransposon-encoded reverse transcriptase modulates the 
expression of cell differentiation genes in breast cancer cells. 
Breast cancer research and treatment 2014;143:239-53. 
13. Hecht M, Harrer T, Buttner M. Cytotoxic effect of efavirenz is 
selective against cancer cells and associated with the 
cannabinoid system. AIDS 2013;27:2031–40.  
14. Sinibaldi-Vallebona P, Lavia P, Garaci E, Spadafora C. A role for 
endogenous reverse transcriptase in tumorigenesis and as a 
target in differentiating cancer therapy. Genes Chromosomes 
Cancer 2006;45:1–10. 
15. Kumar A, Sasmal D, Sharma N, Bhaskar A, Chandra S, 
Mukhopadhyay K, et al. Deltamethrin, a pyrethroid insecticide, 
could be a promising candidate as an anticancer agent. Med 
Hypotheses 2015;85:145-7. 
 
